4 Amendments of Mireille D'ORNANO related to 2017/2154(DEC)
Amendment 2 #
Draft opinion
Paragraph 2
Paragraph 2
2. Notes that in 2016 the total budget of the Agency was EUR 308 422 000; highlights that 89,4 % of the Agency’s revenue came from fees paid by the pharmaceutical industry for services provided, 5,5 % from the Union budget and 5 % from external assigned revenue; points out that the share of the Agency’s revenue that comes from fees paid by the pharmaceutical industry, which is now very high, should be accompanied by increased requirements regarding the Agency's independence from the pharmaceutical industry;
Amendment 4 #
Draft opinion
Paragraph 5
Paragraph 5
5. Welcomes the launch of the clinical data website in October 2016, which represents an important step towards higher transparency; notes that the website gives open access to clinical reports for new medicines for human use authorised in the Union; notes that the Agency is the first regulatory authority worldwide to provide such broad access to clinical data; nevertheless encourages the Agency to continue this important work of providing information for the general public;
Amendment 5 #
Draft opinion
Paragraph 6
Paragraph 6
6. Notes that the Agency set up a taskforce dedicated to ‘Brexit’, which in 2016 was focused on assessing the impact of Brexit on the Agency, with the aim of identifying the main risks, and propose possible mitigating measures; invites this taskforce to work constructively, and to take account of all the positive implications of Brexit for the functioning of the Agency;
Amendment 8 #
Draft opinion
Paragraph 9
Paragraph 9
9. Stresses that the policy on the handling of competing interests of scientific committees' members and experts was updated in October 2016; notes that it includes a clarification on the restrictions regarding the expert's potential employment in a pharmaceutical company and aligns the rules relating to close family members' interests for scientific committee and working party members, with those for the Management Board members; nevertheless encourages the Agency further to strengthen its internal policy on combating conflicts of interest and its independence from the pharmaceutical industry;